FDA Approves Keytruda®
On November 13, 2020, the FDA approved pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of patients with locally recurrent...
Read MoreCreativity to Cope with MBC
If you are diagnosed with MBC, you may live with the disease for years. The stress of treatment side effects, cancer symptoms, uncertainty, and fear can have a...
Read MoreHER2-Low Expressing: A New Subcategory of HER2-Negative Breast Cancer?
Under current treatment guidelines, breast cancer is categorized as HER2-positive or HER2-negative. However, some investigators use the term HER2-low expressing...
Read MoreHow to Prepare for a Virtual SABCS
The San Antonio Breast Cancer Symposium (SABCS) is an important annual breast cancer conference. Last year, SABCS offered more than 1,700 breast cancer-related...
Read MoreMBC, Advanced Breast Cancer & Locally Advanced Breast Cancer: What’s in a Name?
As you search for breast cancer clinical trials, you’ll likely come across language that says the trial is accepting people with “advanced breast...
Read MoreLiving with Metastatic Breast Cancer During October
October is Breast Cancer Awareness Month. It is often marked in mainstream media and pop culture by pink ribbons and talk of survivors and survival. But for many...
Read MoreDifferent Types of Imaging Scans: How, When, and Why They are Used
Scans are a type of imaging that creates pictures of the inside of the body. Scans are used to diagnose metastatic disease, look for new sites of metastasis,...
Read MoreThe Impact of MBC on Work and Career
If you are employed when you receive an MBC diagnosis, you may wonder if you can go to appointments or participate in a clinical trial while continuing to work....
Read MorePD-L1 Biomarker for Immunotherapy
In March 2019, the FDA approved atezolizumab (Tecentriq®), the first PD-1/PD-L1 immune checkpoint inhibitor for metastatic triple-negative breast cancer, based on...
Read MoreSEARCH OUR SITE
for past articles or specific information.